Recent interest in the role of interleukin-37 (IL-37) in NSCLC progression has emerged, with studies suggesting its potential to exert protective effects through various mechanisms, offering new avenues for lung cancer therapy (136). Here, IL37 is linked to non-small cell lung carcinoma.